Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00732836 · ClinicalTrials.gov registry record · Phase 1
Hepatic Arterial Infusion (HAI) of Abraxane
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT00732836: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00732836 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00732836, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The goal of this clinical research study is find the highest tolerated dose of Abraxane (nab-paclitaxel) that can be given directly into the liver of patients with advanced cancer that has spread to the liver.
Interventions
- DRUG HAI Abraxane
- PROCEDURE Hepatic Artery Catheter
- DRUG IV Abraxane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2008-06 |
| Est. Completion | 2016-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00732836
The ClinicalTrials.gov registry entry for NCT00732836 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which HAI Abraxane is the first listed.
NCT00732836 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00732836 about?
NCT00732836 is a clinical study titled "Hepatic Arterial Infusion (HAI) of Abraxane". The goal of this clinical research study is find the highest tolerated dose of Abraxane (nab-paclitaxel) that can be given directly into the liver of patients with advanced cancer that has spread to the liver.
What is the current status of trial NCT00732836?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2008-06. Estimated completion is 2016-01.
What interventions are being tested in trial NCT00732836?
The interventions under investigation include: HAI Abraxane (DRUG), Hepatic Artery Catheter (PROCEDURE), IV Abraxane (DRUG).
Who is sponsoring clinical trial NCT00732836?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.